title: BRCA and pancreatic cancer: selection of chemotherapy.
abstract: Germline mutations in BRCA genes are associated with increased risk of pancreatic cancer. There are pre clinical data which suggests that DNA cross linking agents should be used in pancreatic cancer patients with BRCA mutations. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of pancreatic cancer with BRCA mutation. Only one study (Abstracts #217) was presented and it is described here.
authors.affiliation: H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. richard.kim@moffitt.org
authors.forename: Richard
authors.initials: R
authors.lastname: Kim
authors.forename: Jenifer
authors.initials: J
authors.lastname: Byer
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics*; D019313:BRCA1 Protein / Q000235:genetics*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human